Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Best match
Most recent
Monthly Prescribing Reference
2h
Navacaprant Falls Short in Major Depressive Disorder Trial
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Monthly Prescribing Reference
4h
First Generic Version of Motegrity Approved and Now Available
The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.
Monthly Prescribing Reference
4h
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
FBI: Attacker acted alone
Pulls out of Glastonbury
Pearl Harbor survivor dies
New rules for next Congress
2025 Pro Bowl rosters
Winter storm warnings
‘Dinosaur highway’ tracks
Homemade bombs in Va.
Montenegro mass shooting
Home searched amid probe
Queens nightclub shooting
Hawaii fireworks explosion
'General Hospital’ actor dies
Preinaugural rally in DC
Baldoni files $250M lawsuit
New NC gov. sworn in
Oldest Olympic champ dies
Russian drone strike on Kyiv
Puerto Rico power restored
Broccoli recalled
Russian gas to Europe halted
Quake strikes Lake County
China hacks sanctions office
Israeli airstrikes in Gaza
How to watch Quadrantids
Weekly jobless claims fall
Italy summons Iran envoy
Most on-time airlines in ‘24
Reports 1.1% sales drop
To exit climate alliance
Feedback